subslover
1 año hace
Antonino Morales, Marsha A. Chandler, Bruce E. Gerhardt, Quyen Dao-Haddock, Ivor Royston, and Linda Rubinstein (each a “Member” and collectively the “Members”) tendered their resignations as members of the Company’s Board of Directors which resignations were effective on October 13, 2023, prior to filing the Petition. The resignations of Mr. Morales, Ms. Chandler, Mr. Gerhardt, Ms. Dao-Haddock, Mr. Royston and Ms. Rubinstein are not the result of any disagreements with the Company regarding the Company’s operations, policies, or practices. Each of the Members have resigned due to the Company’s filing of the Petition which effectively eliminates the powers of the Company’s Board of Directors. Following the resignations of the Members, the Company will have no members serving on its Board of Directors.
In addition to his resignation from the Company’s Board of Directors, Mr. Morales tendered his resignation as the Company’s President and Chief Executive Officer effective on October 13, 2023. The resignation of Mr. Morales was not the result of any disagreement with the Company regarding the Company’s operations, policies, or practices. Mr. Morales resigned due to the filing of the Petition which effectively eliminates the powers he previously held on behalf of the Company and the roles of President and Chief Executive Officer.
Awl416
1 año hace
After considering strategic alternatives, Biocept, Inc., a Delaware corporation (the “Company”), filed a voluntary petition for relief (the “Petition”) under the provisions of Chapter 7 of Title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on October 13, 2023
Johnny_C
4 años hace
CEO Michael Nall is a Covid scammer my friend. Not only has he and Biocept CFO Timothy Kennedy been caught red handed committing intentional fraud in SEC filings, they concealed material news from investors. Get ready for another Nall financing.
Nall keeps doubling down on his lies, as he stated that the company announced a supply agreement with Aegea. Well, I do not see a biocept press release or an 8K to that effect. Furthermore, Nall stated that Biocept and Aegea co own Switch Blocker patents decieving investors that Biocept coowns those patents outside of a few oncology indications. This guy is a real piece of work..
Covid testing is going to fall of the cliff, and nearly 95% of the revenue was Covid testing...
In regards to our collaboration with the Aegea Biotechnologies, earlier this month, after successfully developing a next-generation COVID-19 assay, we announced a supply agreement under which Aegea is providing us with the kits for validation and commercialization in our lab. This next-generation COVID-19 assay was developed using the patented Switch-Blocker technology that is jointly owned by Biocept and Aegea, which is the same technology that is the basis for many of our ultrasensitive oncology assays. Our current COVID-19 RT-PCR testing provides qualitative results only, meaning that sample is either positive or negative. The new codeveloped assay has the advantage of distinguishing various strains of the virus while providing quantitative viral load results. Healthcare providers can use this quantitative assay to monitor viral load over time in order to determine when a patient, a resident, student or employee can safely return to the general population. This new assay can also be modified to detect new variants of the SARS-CoV-2 virus as they emerge.
Johnny_C
4 años hace
Maybe, but the press release it typical bullskat.
1. The Aegea test should had an EUA last yr but Nall was incompetent and didn't think Covid testing would last. Because of that they now have had to get cleared which caused delays. A test last September would have had a greater meaining pre vaccine rollout
2. This press release is no different than the one in August that was used to pump the stock to get enough votes to approve a reverse split. Nall tanked the stock with a reverse split and then gave himself 241,000 options at 75% less than the price per share of the first aegea announcement
3. The stock price was higher last febuary before Nall announced Covid testing, the BS VEESure, the Aegea announcements or the new hospital affilaitions for the liquid biopsy.
4. Nall, kennedy and the BOD committed fraud, and the outside attorney and auditor must be in on it because they have not corrected it. Probably because of the class action lawsuit that will have a couple of these execs working a $10.00 an hour job.
Biocept is a good company, lots of hard working people. Stay tuned. I am long till earnings.
This will be the month of pumps and then massive financing because they bleed cash even with Covid testing revenues.
The Aegea announcement does not give them and excusive to sell the test nor does it give them any patent ownership. Typical Biocept press release.
Johnny_C
4 años hace
$bioc $10 with news
Whoo Hoo.. News, like VeeSure, Aegea test kit or that they have now done 200,000 Covid tests... Sure it will go up and then a $10, $20, $30 million dollar financing will be disclosed after hours.
And if the past proves the future the stock will tank in after hours, the past shows it tanking 50% off the high of the day and then a financing will be done.
Is it true the CEO Nall received $3 million plus bonus for doing the financings the last year. It is not to hard to raise money when you do it at half price with news in your back pocket.
It sure is trus CEO Nall granted himself 241,000 options at $4.40 (.45 pps pre reverse split) a share after the stock was $13 (1.30 pps pre reverse split)
TIC TOC..
For reference, the stock price hit $7.80 last Febuary before any CoVid testing, VeeSure or Aegea test kit announcement.
The stock price was $13 last August on the Aegea test kit news. Yet despite all the testing, which according to a press release a few months ago was 25,000,000 tests ($25,000,000 in revenue) plus the VeeSure plus the Aegea test kit the stock is still at $6.50 (or .65 before the reverse split)
maybe you $10, $12 but one doesn't need a crystal ball to see a financing in the future. Small companies need financing for sure, but BIOC has a liquid biopsy product that has been out for a while and all they do is lose money. Testing for covid will slow down by EOY.